Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11736720&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis Chan HL; Tang JL; Tam W; Sung JJAliment Pharmacol Ther 2001[Dec]; 15 (12): 1899-905BACKGROUND: Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent. AIM: To conduct a meta-analysis to evaluate the efficacy of thymosin treatment in chronic hepatitis B virus infection. METHODS: Randomized controlled trials comparing thymosin for over 24 weeks vs. placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials. Biochemical (normalization of transaminases) and virological (loss of hepatitis B virus DNA and hepatitis B e antigen) responses were analysed using the intention-to-treat method. The odds ratio was used to measure the magnitude of the efficacy. RESULTS: Five trials (353 patients) were identified. The odds ratio (95% confidence interval) of the virological response of thymosin over placebo at the end of treatment, 6 months post-treatment and 12 months post-treatment were 0.56 (0.2-1.52), 1.67 (0.83-3.37) and 2.67 (1.25-5.68), respectively. There was an increasing trend of the virological response with time since the cessation of thymosin treatment (P=0.02). There was no difference in the biochemical response between the thymosin and placebo groups at the end of treatment, 6 months post-treatment and 12 months post-treatment. CONCLUSIONS: Thymosin is effective in suppressing viral replication in chronic hepatitis B virus infection, but the effect is delayed until 12 months after the cessation of treatment.|Antiviral Agents/*therapeutic use[MESH]|DNA, Viral/analysis[MESH]|Hepatitis B e Antigens/analysis[MESH]|Hepatitis B virus/*drug effects/genetics/pathogenicity[MESH]|Hepatitis B, Chronic/*drug therapy/immunology/virology[MESH]|Humans[MESH]|MEDLINE[MESH]|Odds Ratio[MESH]|Randomized Controlled Trials as Topic[MESH]|Thymosin/immunology/*therapeutic use[MESH]|Transaminases/analysis[MESH]|Treatment Outcome[MESH] |
